বেলজিয়াম - ইংরেজি - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - acetylcysteine 200 mg - oral powder - 200 mg - acetylcysteine 200 mg - acetylcysteine

বেলজিয়াম - ইংরেজি - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - acetylcysteine 600 mg - effervescent tablet - 600 mg - acetylcysteine 600 mg - acetylcysteine

যুক্তরাজ্য - ইংরেজি - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen healthcare ltd - acetylcysteine - oral capsule - 600mg

আয়ার্লণ্ড - ইংরেজি - HPRA (Health Products Regulatory Authority)

stirling anglian pharmaceuticals ireland limited - acetylcysteine - effervescent tablet - 600 milligram(s) - mucolytics; acetylcysteine

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

exela pharma sciences, llc - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (rsi). acetylcysteine injection is contraindicated in patients with a previous hypersensitivity reaction to acetylcysteine [see warnings and precautions (5.1)] . risk summary limited published case reports and case series of pregnant women exposed to acetylcysteine during various trimesters are not sufficient to inform any drug associated risk. delaying treatment of acetaminophen overdose may increase the risk of maternal or fetal morbidity and mortality [see clinical considerations]. reproduction studies in rats and rabbits following oral administration of acetylcysteine during the period of organogenesis at doses similar to the total intravenous dose (based on the body surface area) did not cause any adverse effects to the fetus. the estimated background risk of major birth defects and mi

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

sagent pharmaceuticals - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (rsi). acetylcysteine is contraindicated in patients with a previous hypersensitivity reaction to acetylcysteine [see warnings and precautions (5.1)] . risk summary limited published case reports and case series of pregnant women exposed to acetylcysteine during various trimesters are not sufficient to inform any drug associated risk. delaying treatment of acetaminophen overdose may increase the risk of maternal or fetal morbidity and mortality [see clinical considerations]. reproduction studies in rats and rabbits following oral administration of acetylcysteine during the period of organogenesis at doses similar to the total intravenous dose (based on the body surface area) did not cause any adverse effects to the fetus. the estimated background risk of major birth defects and miscarriage

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

indoco remedies limited - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (rsi). acetylcysteine injection is contraindicated in patients with a previous hypersensitivity reaction to acetylcysteine [see warnings and precautions (5.1)] . risk summary limited published case reports and case series of pregnant women exposed to acetylcysteine during various trimesters are not sufficient to inform any drug associated risk. delaying treatment of acetaminophen overdose may increase the risk of maternal or fetal morbidity and mortality [see clinical considerations]. reproduction studies in rats and rabbits following oral administration of acetylcysteine during the period of organogenesis at doses similar to the total intravenous dose (based on the body surface area) did not cause any adverse effects to the fetus. the estimated background risk of major birth defects and mi

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

baxter healthcare corporation - cysteine hydrochloride (unii: zt934n0x4w) (cysteine - unii:k848jz4886) - cysteine hydrochloride injection, usp is indicated for use as an additive to amino acids solutions to meet nutritional requirements of neonates (preterm and term infants less than one month of age) requiring total parenteral nutrition. cysteine hydrochloride injection, usp is contraindicated in: risk summary cysteine hydrochloride injection, usp for use as an additive to amino acid solutions to meet nutritional requirements is not indicated for use in adults. appropriate administration of cysteine hydrochloride injection, usp is not expected to cause major birth defects, miscarriage or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with cysteine hydrochloride. risk summary cysteine hydrochloride injection, usp is used as an additive to amino acid solutions to meet nutritional requirements of neonates requiring total parenteral nutrition and is not indicated for use in adults. there are no data on the presence of cysteine hydrochloride in human or animal milk or the effects on milk production. data available on the effects of cysteine hydrochloride on infants, either directly or through breastmilk, do not suggest a significant risk of adverse reactions from exposure. cysteine hydrochloride injection, usp is indicated for use as an additive to amino acid solutions to meet the nutritional requirements of neonates, including preterm infants, requiring total parenteral nutrition. the safety profile for cysteine hydrochloride injection, usp use in neonates includes risks of acid-base imbalance and hepatobiliary dysfunction. acid-base imbalance, including metabolic acidosis, and liver dysfunction may occur with cysteine hydrochloride injection, usp administration in preterm infants. frequent clinical and laboratory assessments are necessary to monitor and manage fluid balance, electrolyte concentrations, liver tests, and acid-base balance during parenteral nutrition therapy [see warnings and precautions (5.4)]. hyperammonemia is of special significance in neonates. this reaction appears to be related to a deficiency of the urea cycle amino acids of genetic or product origin. it is essential that blood ammonia be measured during treatment [see warnings and precautions (5.5)]. because of immature renal function, neonates including preterm infants, receiving prolonged parenteral nutrition with cysteine hydrochloride injection, usp may be at higher risk of aluminum toxicity [see warnings and precautions (5.7)].

আয়ার্লণ্ড - ইংরেজি - HPRA (Health Products Regulatory Authority)

ascot laboratories (ireland) limited - acetylcysteine - effervescent tablet - mucolytics; acetylcysteine

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

almaject, inc. - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (rsi). acetylcysteine injection is contraindicated in patients with a previous hypersensitivity reaction to acetylcysteine [see warnings and precautions (5.1)] . risk summary limited published case reports and case series of pregnant women exposed to acetylcysteine during various trimesters are not sufficient to inform any drug associated risk. delaying treatment of acetaminophen overdose may increase the risk of maternal or fetal morbidity and mortality [see clinical considerations] . reproduction studies in rats and rabbits following oral administration of acetylcysteine during the period of organogenesis at doses similar to the total intravenous dose (based on the body surface area) did not cause any adverse effects to the fetus. the estimated background risk of major birth defects and mi